Lowest-Rated StocksLowest-Rated Amedisys Stock Price, News & Analysis (NASDAQ:AMED) $93.94 +0.21 (+0.22%) (As of 11:03 AM ET) Add Compare Share Share Today's Range$93.44▼$94.1750-Day Range$91.15▼$94.0952-Week Range$69.36▼$106.01Volume40,310 shsAverage Volume476,257 shsMarket Capitalization$3.07 billionP/E Ratio1,342.19Dividend YieldN/APrice Target$103.55 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.18 Rating ScoreUpside/Downside10.2% Upside$103.55 Price TargetShort InterestHealthy7.75% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth0.68%From $4.39 to $4.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector545th out of 960 stocksMedical Care Facilities Industry6th out of 7 stocks 2.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.55, Amedisys has a forecasted upside of 10.2% from its current price of $93.95.Amount of Analyst CoverageAmedisys has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.75% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Amedisys has recently decreased by 5.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.5 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amedisys this week, compared to 3 articles on an average week.Search Interest2 people have searched for AMED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions95.70% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 0.68% in the coming year, from $4.39 to $4.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 1,342.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 1,342.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 130.61.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Short Interest Down 5.7% in NovemberDecember 3, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Coverage Initiated by Analysts at StockNews.comDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 24, 2023 | finance.yahoo.comChemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?November 23, 2023 | finance.yahoo.comAmedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?October 26, 2023 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comAmedisys' (AMED) Q3 Earnings Miss Estimates, Margins UpOctober 25, 2023 | msn.comAmedisys Non-GAAP EPS of $0.98 misses by $0.09, revenue of $556.24M misses by $4.51MDecember 8, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.October 25, 2023 | finance.yahoo.comAmedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to SayOctober 24, 2023 | msn.comAmedisys (AMED) Q3 Earnings and Revenues Lag EstimatesOctober 24, 2023 | finance.yahoo.comAmedisys Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | finance.yahoo.comAmedisys Inc (AMED) Reports Q3 2023 Earnings: Net Income Rises Despite Decrease in Net Service ...October 19, 2023 | finance.yahoo.comAPCI to Feds: Stop Further Healthcare Vertical Integration in Optum-Amedisys DealOctober 18, 2023 | finance.yahoo.comAmedisys Celebrates National Quality WeekOctober 5, 2023 | msn.comElizabeth Warren Asks Regulators to Scrutinize UnitedHealth-Amedisys Acquisition DealOctober 4, 2023 | msn.comSen. Elizabeth Warren urges regulators to scrutinize Amedisys/UnitedHealth dealOctober 3, 2023 | finance.yahoo.com15 Most Competitive Residency Programs in USSeptember 28, 2023 | finance.yahoo.comKey Players in the Long Term Care Market Include Amedisys, Humana, and Sunrise Senior Living - Forecast 2023-2030September 14, 2023 | markets.businessinsider.comCantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To KnowSeptember 14, 2023 | msn.comCantor Fitzgerald Maintains Amedisys (AMED) Neutral RecommendationAugust 15, 2023 | msn.comSignal: UnitedHealth’s Amedisys acquisition under further DOJ scrutinyAugust 14, 2023 | bizjournals.comTravis Messina named CEO of Regent Surgical HealthJuly 28, 2023 | finance.yahoo.comAmedisys (AMED) Q2 Earnings Beat Estimates, Margins DipJuly 28, 2023 | msn.comCredit Suisse Reiterates Amedisys (AMED) Neutral RecommendationJuly 28, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About AmedisysJuly 27, 2023 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Second Quarter 2023 Financial ResultsSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/24/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Care Facilities Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees18,600Year Founded1982Price Target and Rating Average Stock Price Target$103.55 High Stock Price Target$125.00 Low Stock Price Target$81.00 Potential Upside/Downside+10.5%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E Ratio1,339.19 Forward P/E Ratio21.35 P/E Growth2.55Net Income$118.61 million Net Margins0.12% Pretax Margin2.32% Return on Equity13.45% Return on Assets7.45% Debt Debt-to-Equity Ratio0.34 Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$2.23 billion Price / Sales1.37 Cash Flow$7.30 per share Price / Cash Flow12.84 Book Value$34.06 per share Price / Book2.75Miscellaneous Outstanding Shares32,633,000Free Float32,046,000Market Cap$3.06 billion OptionableOptionable Beta0.92 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Scott G. Ginn (Age 54)Executive VP, COO, CFO & Principal Financial Officer Comp: $659.94kMr. Michael P. North (Age 58)Chief Information Officer Comp: $442.38kMs. Denise Bohnert (Age 45)Chief Compliance Officer Comp: $399.72kMr. Nick Muscato (Age 37)Chief Strategy Officer Comp: $400.94kMr. Richard M. Ashworth (Age 48)President, CEO & Director Ms. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMr. Pete HartleyCTO & Senior VP of Business Operations SystemsMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 52)Chief People Officer More ExecutivesKey CompetitorsAddus HomeCareNASDAQ:ADUSAdaptHealthNASDAQ:AHCOOption Care HealthNASDAQ:OPCHEvolent HealthNYSE:EVHTeladoc HealthNYSE:TDOCView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 150,240 shares on 12/7/2023Ownership: 0.510%Wellington Management Group LLPSold 602,542 shares on 12/1/2023Ownership: 3.007%Carmignac GestionBought 26,598 shares on 11/29/2023Ownership: 0.103%Deutsche Bank AGSold 35,104 shares on 11/24/2023Ownership: 0.005%Comerica BankSold 3,963 shares on 11/21/2023Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price target for 2024? 11 brokerages have issued 12-month target prices for Amedisys' stock. Their AMED share price targets range from $81.00 to $125.00. On average, they predict the company's share price to reach $103.55 in the next year. This suggests a possible upside of 10.2% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2023? Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED shares have increased by 12.5% and is now trading at $93.95. View the best growth stocks for 2023 here. Are investors shorting Amedisys? Amedisys saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,470,000 shares, a drop of 5.7% from the October 31st total of 2,620,000 shares. Based on an average trading volume of 371,100 shares, the days-to-cover ratio is presently 6.7 days. Currently, 7.8% of the shares of the company are short sold. View Amedisys' Short Interest. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its earnings results on Tuesday, October, 24th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.08 by $0.10. The health services provider had revenue of $556.24 million for the quarter, compared to the consensus estimate of $560.23 million. Amedisys had a net margin of 0.12% and a trailing twelve-month return on equity of 13.45%. Amedisys's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.15 earnings per share. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), SRH U.S. Quality ETF (SRHQ), SPDR S&P Health Care Services ETF (XHS) and IQ Merger Arbitrage ETF (MNA).iShares U.S. Healthcare Providers ETF (IHF). What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). Who are Amedisys' major shareholders? Amedisys' stock is owned by many different retail and institutional investors. Top institutional investors include Pentwater Capital Management LP (3.51%), Alpine Associates Management Inc. (3.17%), Wellington Management Group LLP (3.01%), Mackenzie Financial Corp (2.88%), Westchester Capital Management LLC (2.61%) and Van Lanschot Kempen Investment Management N.V. (1.28%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AMED) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.